Alumis Stock Has Rallied 250% This Past Year. One Fund Sold Its $5 Million Stake Last Quarter.

BML Capital Management fully liquidated its 1,210,415-share stake in Alumis (NASDAQ:ALMS) in the fourth quarter, a sale worth roughly $4.83 million and previously representing about 4.4% of the fund's AUM. Alumis shares traded at $26.42 (as of early February), up ~255% year-over-year; the company has a $3.3 billion market cap, $22.12 million TTM revenue and a ($245.15) million TTM net loss. The sale was executed by the quarter-end (Dec. 31) before Alumis's January upsized offering removed balance-sheet risk and precipitated a subsequent ~200% rally, suggesting the fund's exit was risk/exposure management rather than a negative read on the science.

Analysis

Market structure: The ALMS upsized offering shifted the short-term supply/demand equation — issuance removed immediate solvency risk (benefitting holders and risk-tolerant momentum buyers) and increased free float that was rapidly absorbed by buyers, producing a ~200% post-offer rally. Winners: underwriters, long-biotech momentum accounts, and well-capitalized peers; losers: disciplined allocators (e.g., BML) who trimmed pre-offer and missed the rally and concentrated retail sellers pre-offer. Cross-asset: limited macro spillover but expect tighter credit spreads for small-cap biotech debt and higher implied vol in biotech options; FX/commodities unaffected.

Risk assessment: Key tail risks are clinical failure (binary, 0–100% impact), subsequent dilutive raises if cash burn exceeds runway, and regulatory setbacks; a single pivotal trial miss could unwind >50–80% of the post-offer re-rate. Time horizons: immediate (days-weeks) dominated by momentum and gamma flows; short-term (3–6 months) driven by enrollment and secondary market sentiment; long-term (12–24 months) driven by data readouts and commercial viability. Hidden dependencies include retail/options gamma, lock-up/insider sales windows, and correlated funding cycles across early-stage TYK2 peers.

Trade implications: For disciplined risk, prefer defined-risk, event-linked trades sized small (1–2% portfolio). Direct: tactical long ALMS via 3-month call debit spread to capture continued re-rate into upcoming clinical milestones while capping downside. Pairs: long ALMS vs short XBI (or IBB) to isolate company-specific upside; or hedge a biotech book with 3-month XBI puts sized to protect 10–20% exposure. Exit rules: trim on +50% move or on price breach of -25% from entry; reassess at each clinical/cash milestone.

Contrarian angle: The market conflates financing removal with scientific derisking — financing fixes solvency but does not change PoS; consensus may be overpaying for optionality. Historical parallels (biotechs that popped after financings then collapsed on trials) argue for selling into strength or using collars once you have >50% unrealized gains. Unintended consequence: higher valuation raises future dilution risk and forces accelerated timelines that can increase operational execution risk.

Key Decisions for Investors

• Establish a tactical long in ALMS (NASDAQ:ALMS) sized 1% of portfolio via a 3-month call debit spread (buy ATM, sell ~20% OTM) to capture momentum into next 3 months; cap max loss to 1% portfolio, take profits at +50% or exit on a drop below $20 (~25% downside from $26.42).
• Reduce single-name early-stage biotech concentration by 25% vs current weights if any name >3% portfolio; redeploy proceeds into larger, better-funded biotechs or AVIR (ticker AVIR) with a 6–12 month hold and initial sizing 1–2% of portfolio.
• Hedge sector tail risk: buy 3-month put protection on XBI sized to cover 10–20% of biotech exposure (or short equivalent notional of IBB) if biotech weight >5% of portfolio; close hedge after significant vol compression (>30%) or when biotech index falls 15%.
• If holding ALMS outright after >50% unrealized gain, implement a collar (sell near-term calls to fund 3–6 month puts) to lock gains while retaining limited upside; unwind collar if clinical PoS materially increases (e.g., positive interim readout within 3 months).